News & Perspective

Jul 26, 2006

Jul 26, 2006

Glaxo says its H5N1 vaccine works at low dose

(CIDRAP News) – An H5N1 avian influenza vaccine made by GlaxoSmithKline (GSK) triggered a good immune response in human volunteers at a much lower dose than other H5N1 vaccines reported so far, which means that hundreds of millions of doses could be produced by next year, the company announced today.